AngioDynamics Executive and Leadership Team

Yoel Zabar, the Chief Executive Officer at AngioDynamics, directs the overarching corporate strategy to ensure long-term growth within the medical device sector. Overseeing the alignment of internal resources with global market demands, the Chief Executive Officer drives initiatives that enhance patient outcomes through technological advancement. Yoel Zabar manages high-level stakeholder relationships and coordinates with the board to maintain operational excellence across worldwide facilities. By prioritizing the development of high-quality medical devices, the Chief Executive Officer secures a competitive advantage in complex healthcare environments. This leadership role involves constant evaluation of market trends to pivot the company toward emerging opportunities. Through rigorous oversight of organizational performance, the Chief Executive Officer fosters a culture of innovation. Ultimately, Zabar ensures the company remains a reliable partner for the global medical community while delivering consistent value to shareholders and patients alike.

Eric Honroth, the President & Chief Executive Officer at AngioDynamics, executes the primary operational vision to expand the company footprint in international healthcare markets. Directing the integration of strategic partnerships and distribution networks, the President & Chief Executive Officer optimizes the delivery of medical solutions to diverse clinical settings. Eric Honroth monitors the efficiency of global operations to ensure that product quality meets stringent regulatory standards. By leading cross-functional teams, the President & Chief Executive Officer accelerates the commercialization of new medical devices. This role requires constant interaction with regional leaders to adapt business models to local healthcare needs. Through the implementation of scalable processes, the President & Chief Executive Officer strengthens the market position of the organization. Honroth maintains a focus on sustainable growth, ensuring that every operational decision supports the broader mission of improving patient care on a global scale.

Steve Trowbridge, the Executive Vice President & Chief Financial Officer at AngioDynamics, manages the fiscal health and capital allocation strategies required to support global operations. Overseeing financial planning, reporting, and risk management, the Executive Vice President & Chief Financial Officer ensures that resources are directed toward high-impact growth areas. Steve Trowbridge coordinates with the executive team to analyze the financial viability of new product launches and market expansions. By maintaining transparent communication with investors and regulatory bodies, the Executive Vice President & Chief Financial Officer upholds the integrity of the corporate balance sheet. This leadership role involves optimizing cost structures to improve operational efficiency across all international divisions. Through disciplined financial oversight, Trowbridge provides the stability necessary for the company to pursue long-term innovation. Ultimately, the Executive Vice President & Chief Financial Officer secures the financial foundation that allows the organization to continue its mission of improving patient outcomes.

Ilan Ben-Oren, the Chief Technology Officer & Founder & At Angiodynamics Since Oct 2019) Director, Research & Development at AngioDynamics, architects the technical roadmap for next-generation medical device innovation. Overseeing the research and development pipeline, the Chief Technology Officer & Founder & At Angiodynamics Since Oct 2019) Director, Research & Development translates clinical needs into high-quality engineering solutions. Ilan Ben-Oren manages the laboratory teams and technical staff to ensure that product design aligns with the latest advancements in medical science. By fostering a collaborative environment, the Chief Technology Officer & Founder & At Angiodynamics Since Oct 2019) Director, Research & Development drives the creation of proprietary technologies that differentiate the company in the marketplace. This leadership role involves rigorous testing and validation protocols to guarantee safety and efficacy. Through continuous investment in R&D, Ben-Oren ensures the company remains at the forefront of medical technology, consistently delivering tools that improve patient outcomes worldwide.